Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Keystone Nano Announces FDA Approval of Investigational New Drug Application for Ceraxa for the Treatment of Acute Myeloid Leukemia

Abstract:
Keystone Nano, Inc., a biopharmaceutical company focused on improving cancer treatments through the application of novel treatments and nanotechnology, announced today that the U.S. Food and Drug Administration has approved the company’s Investigational New Drug (IND) Application to assess Ceraxa in the treatment of Acute Myeloid Leukemia (AML). This new approval leverages the company’s ongoing successful Ceraxa clinical trial by allowing the exploration of Ceraxa for cancer patients with AML.

Keystone Nano Announces FDA Approval of Investigational New Drug Application for Ceraxa for the Treatment of Acute Myeloid Leukemia

State College, PA | Posted on September 18th, 2019

The company’s AML initial drug testing will be conducted at the University of Virginia and Memorial Sloan Kettering. The clinical trial will enable the Keystone Nano to test safety and efficacy of Ceraxa to establish a safe dose level and begin gathering information about the its benefits as a cancer therapy.

“This approval allows us to test our therapy for patients with AML”, noted Jeff Davidson, Keystone Nano’s CEO. “We are excited by the Phase I solid tumor study results to date and the lack of adverse events in clinical testing and evidence of patient benefit, and we look forward to continuing to evaluate Ceraxa for human use. This is a significant step forward in the development of Ceraxa for the treatment of AML.”.

Ceraxa is a bioactive lipid that has shown efficacy in AML as well as in breast cancer, liver cancer, and pancreatic cancer. Evidence collected in a large number of research tests and now in the clinic has clearly demonstrated that Ceraxa kills cancer cells while leaving normal cells alone, providing treatment without undue toxicity.

The Phase I portion of the AML trial will recruit patients with to establish dosing and safety. AML kills approximately 11,000 people in the United States. There are currently limited effective therapies for this disease and the five-year survival rate is approximately 27%. Keystone Nano was recently awarded orphan drug status for the treatment of AML with ceramides in the United States.

####

About Keystone Nano, Inc.
Based in State College, PA, Keystone Nano is working at the interface between nanotechnology and the life sciences. In addition to developing Ceraxa, the company is working on additional products using NanoJackets, calcium phosphate nanoparticles that may be targeted to specific cell types, for a variety of medical applications including RNA delivery and immuno-therapy. The Company’s product pipeline is protected by a patent portfolio comprised of 11 patent families that has resulted in 14 issued patents and 8 pending applications to date. More detail can be found at Keystone’s web site, including links to numerous published papers that describe Keystone’s technology and the results to date.

For more information, please click here

Contacts:
Jeff Sirianni

Managing Member
Monarch Solutions, LLC
Mobile: (703) 728.6837
www.Monarchsls.com

Copyright © Keystone Nano, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Keystone has a 90 second animation that describes its technology at:

Related News Press

News and information

INRS and ELI deepen strategic partnership to train the next generation in laser science:PhD students will benefit from international mobility and privileged access to cutting-edge infrastructure June 6th, 2025

Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025

Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025

A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025

Videos/Movies

New X-ray imaging technique to study the transient phases of quantum materials December 29th, 2022

Solvent study solves solar cell durability puzzle: Rice-led project could make perovskite cells ready for prime time September 23rd, 2022

Scientists prepare for the world’s smallest race: Nanocar Race II March 18th, 2022

Visualizing the invisible: New fluorescent DNA label reveals nanoscopic cancer features March 4th, 2022

Govt.-Legislation/Regulation/Funding/Policy

INRS and ELI deepen strategic partnership to train the next generation in laser science:PhD students will benefit from international mobility and privileged access to cutting-edge infrastructure June 6th, 2025

Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025

Institute for Nanoscience hosts annual proposal planning meeting May 16th, 2025

Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025

Possible Futures

Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025

Researchers unveil a groundbreaking clay-based solution to capture carbon dioxide and combat climate change June 6th, 2025

Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025

A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025

Nanomedicine

Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025

Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025

Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025

Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025

Announcements

INRS and ELI deepen strategic partnership to train the next generation in laser science:PhD students will benefit from international mobility and privileged access to cutting-edge infrastructure June 6th, 2025

Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025

Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025

A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025

Nanobiotechnology

Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025

Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025

Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025

Low-cost formulation reduces dose and increases efficacy of drug against worms: Praziquantel, usually administered in large tablets, is the only anthelmintic available on the market. New form of presentation uses nanotechnology and facilitates use by children and pets May 16th, 2025

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project